Table 3 Univariate analysis of baseline characteristics according to tumour response and time to progression (TTP)
Tumour response | TTP | |||||
|---|---|---|---|---|---|---|
Odds ratio | 95% confidence interval | P | Hazard ratio | 95% confidence interval | P | |
Agea | 1.01 | (0.97; 1.06) | 0.587 | 0.98 | (0.95; 1.01) | 0.189 |
Gender (F vs M) | 1.44 | (0.53; 3.91) | 0.468 | 0.74 | (0.40; 1.39) | 0.347 |
Body mass indexa | 1.32 | (0.99; 1.29) | 0.069 | 0.86 | (0.78; 0.95) | 0.002 |
Pancreatic primary tumour | 1.33 | (0.45; 3.93) | 0.610 | 1.11 | (0.56; 2.17) | 0.769 |
Functioning tumour | 3.83 | (1.27; 11.52) | 0.016 | 0.72 | (0.39; 1.33) | 0.299 |
Primary lesion diametera | 0.77 | (0.57; 1.03) | 0.08 | 1.14 | (1.02; 1.28) | 0.019 |
Resected primary lesion | 0.76 | (0.27; 2.18) | 0.615 | 1.4 | (0.75; 2.62) | 0.287 |
Extra-hepatic lesion(s) | 0.83 | (0.30; 2.30) | 0.716 | 1.6 | (0.87; 2.96) | 0.131 |
Previous chemotherapy | 0.97 | (0.32; 2.92) | 0.96 | 1.75 | (0.92; 3.35) | 0.091 |
Progressive or aggressive disease | 0.56 | (0.20; 1.64) | 0.284 | 1.37 | (0.69; 2.74) | 0.371 |
Concomitant treatment with somatostatin analogues | 0.91 | (0.33; 2.55) | 0.864 | 1.27 | (0.69; 2.35) | 0.447 |
MIB-1a | 0.85 | (0.67; 1.09) | 0.197 | 1.04 | (1.004; 1.069) | 0.026 |
Hepatic lesion longest diametera | 0.99 | (0.97; 1) | 0.22 | 1.01 | (0.99; 1.01) | 0.314 |
Liver replacement >50% | 0.57 | (0.20; 1.66) | 0.305 | 1.98 | (1.06; 3.70) | 0.033 |
Arterial phase enhancement | 2.55 | (0.72; 9.02) | 0.146 | 0.58 | (0.3; 1.14) | 0.115 |
Hepatic lesion homogeneous pattern | 0.99 | (0.31; 3.18) | 0.985 | 0.87 | (0.41; 1.87) | 0.728 |
Streptozotocin vs doxorubicin | 2.83 | (0.88; 9.04) | 0.073 | 0.997 | (0.49; 2.02) | 0.993 |
